



#14/7D
(ok)

Case No. 033.10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,984

Filed: 02 April 2001

For: METHODS EMPLOYING
GENERALIZED TARGET-
BINDING E-TAG PROBES

Examiner: J. Tung

Art Unit: 1637

TERMINAL DISCLAIMER UNDER
37 C.F.R. 1.321©

Assistant Commissioner of Patents
Washington, D. C. 20231


Sir:

The owner, Aclara Biosciences, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/824,851, filed on 02 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent granted, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.

07/25/2002 AHONDAF1 00000153 502266 09824984
11 FC:248 55.00 CH


Stephen C. Macevicz
Reg. No. 30,285

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

RECEIVED
JUL 26 2002
TECHNICAL CENTER 1600/2900
July 22, 2002



Case No. 033.10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,984

Filed: 02 April 2001

For: METHODS EMPLOYING
GENERALIZED TARGET-
BINDING E-TAG PROBES

Examiner: J. Tung

Art Unit: 1637

TERMINAL DISCLAIMER UNDER
37 C.F.R. 1.321©

Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

The owner, Aclara Biosciences, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/824,861, filed on 02 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent granted, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.

07/25/2002 AHONDAF1 00000153 502266 09824984

10 FC:248

55.00 CH


Stephen C. Macevicz
Reg. No. 30,285

July 22, 2002
Date

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

RECEIVED
JUL 26 2002
TECH CENTER
1600/2900



#16/rd (Oke)
Case No. 033.10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,984

Filed: 02 April 2001

For: METHODS EMPLOYING
GENERALIZED TARGET-
BINDING E-TAG PROBES

Examiner: J. Tung

Art Unit: 1637

TERMINAL DISCLAIMER UNDER
37 C.F.R. 1.321©

Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

The owner, Aclara Biosciences, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/824,905, filed on 02 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent granted, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.

07/25/2002 AHONDAF1 00000153 502266 09824984

09 FC:248

55.00 CH

Stephen C. Macevicz
Reg. No. 30,285

RECEIVED
JUL 22 2002
Date
TECH CENTER 1600/2900

Terminal disclaimer fee under 37 CFR 1.20(d) is included.



#17/TD
(OR)

Case No. 033.10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,984

Filed: 02 April 2001

For: METHODS EMPLOYING
GENERALIZED TARGET-
BINDING E-TAG PROBES

Examiner: J. Tung

Art Unit: 1637

TERMINAL DISCLAIMER UNDER
37 C.F.R. 1.321©

Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

The owner, Aclara Biosciences, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/825,244, filed on 02 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent granted, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.

07/25/2002 AHONDAF1 00000153 502266 09824984

05 FC:240

55.00 CH


Stephen C. Macevicz
Reg. No. 30,285

July 22, 2002
Date

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

#18/1D
(ok)



Case No. 033.10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,984

Filed: 02 April 2001

For: METHODS EMPLOYING
GENERALIZED TARGET-
BINDING E-TAG PROBES

Examiner: J. Tung

Art Unit: 1637

TERMINAL DISCLAIMER UNDER
37 C.F.R. 1.321©

Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

The owner, Aclara Biosciences, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/825,245, filed on 02 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent granted, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.

07/25/2002 AWONDAF1 00000153 502266 09824984

07 FC:248

55.00 CH


Stephen C. Macevicz
Reg. No. 30,285

July 22, 2002
Date

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

TECH CENTER 1600/2900

JUL 26 2002

RECEIVED

#19/TD
(OK)

Case No. 033.10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,984

Filed: 02 April 2001

For: METHODS EMPLOYING
GENERALIZED TARGET-
BINDING E-TAG PROBES

Examiner: J. Tung

Art Unit: 1637

TERMINAL DISCLAIMER UNDER
37 C.F.R. 1.321©Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

The owner, Aclara Biosciences, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/825,246, filed on 02 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent granted, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.

07/25/2002 AMONDAF1 00000153 502266 09824984

08 FC:248

55.00 CH

Stephen C. Macevicz
Reg. No. 30,285

July 22, 2002

TECH
CENTER 1600/2900

JUL 26 2002

RECEIVED

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

42077D
(OK)
Case No. 033.10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Singh

Serial No: 09/824,984

Filed: 02 April 2001

For: METHODS EMPLOYING
GENERALIZED TARGET-
BINDING E-TAG PROBES

Examiner: J. Tung

Art Unit: 1637

TERMINAL DISCLAIMER UNDER
37 C.F.R. 1.321©

Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

The owner, Aclara Biosciences, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/825,247, filed on 02 April 2001, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent granted, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned is an attorney or agent of record.

07/25/2002 AHONDAF1 00000153 502266 09824984

03 FC:240

55.00 CH


Stephen C. Macevicz
Reg. No. 30,285

July 22, 2002
Date

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

RECEIVED
JUL 26 2002
TECH CENTER 1600/2900